Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 24, 2009

Alpco to Market Athera’s Cardiovascular Biomarker ELISA Kit in North America

  • Alpco negotiated North American distribution rights to Swedish company Athera’s CVDefine® research-use ELISA kit for the quantitative analysis of anti-PC in human blood. The cardiovascular disease biomarker test has been developed to help the early detection of lesions in the artery wall caused by inflammation. A CE-marked CVDefine kit is available in Europe.
    CVDefine is the first product in Athera’s diagnostic pipeline.

    The company, part of the Karolinska Development portfolio, is focused on developing novel products for the treatment and prevention of cardiovascular disease.

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.